Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts
- 5 November 2018
- journal article
- review article
- Published by Wiley in American Journal of Hematology
- Vol. 94 (2) , 257-265
Abstract
Measurable residual disease (MRD) that persists after initial therapy is a powerful predictor of relapse and survival in acute lymphoblastic leukemia (ALL). However, the optimal use of this information to influence therapeutic decisions is controversial. Herein, we comprehensively review the role of MRD assessment in adults with ALL, including methods to quantify residual leukemia cells during remission, prognostic impact of MRD across ALL subtypes, and available therapeutic approaches to eradicate MRD. This review presents consensus statements and provides an evidence‐based framework for practicing hematologists and oncologists to use MRD information to make rational treatment decisions in adult patients with ALL.Keywords
Funding Information
- PLATO (Physicians Learning and Teaching in Oncology) Foundation
This publication has 76 references indexed in Scilit:
- Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologiesBlood, 2015
- Immunoglobulin and T Cell Receptor Gene High-Throughput Sequencing Quantifies Minimal Residual Disease in Acute Lymphoblastic Leukemia and Predicts Post-Transplantation Relapse and SurvivalTransplantation and Cellular Therapy, 2014
- Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemiaBlood, 2014
- Treatment of High-Risk Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 TrialJournal of Clinical Oncology, 2014
- UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemiaBlood, 2014
- Has MRD monitoring superseded other prognostic factors in adult ALL?Blood, 2012
- Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapiesBlood, 2012
- Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trialBritish Journal of Haematology, 2012
- Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemiaBlood, 2006
- Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALLLeukemia, 2002